UnknownPhase 1

Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets

GermanyStarted 2004-08

Plain-language summary

X-linked hypophosphatemic rickets (XLH) is characterized by rickets, disproportionate short stature, impaired renal phosphate reabsorption and vitamin D metabolism. Despite oral phosphate and vitamin D treatment, most children with XLH demonstrate reduced adult height. The main objective of the study is to determine the beneficial effects of recombinant human growth hormone (rhGH) therapy on body proportions after 36 month in these patients. Secondary objective is to monitor side effects of the therapy.

Who can participate

Age range3 Years – 10 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Tanner stages of puberty B1, G1 * body height \< 2,5 SDS * growth velocity \< 75% * confirmed diagnosis of XLHR * conservative treatment for at least 1 year (phosphate, vitamin D) * informed consent, written agreement Exclusion Criteria: * growth hormone deficiency * hypothyreosis * severe rickets * severe physical deformities * severe hyperparathyreoidism * chronic renal failure * complex syndrome involving failure to thrive * chronic disease with failure to thrive * impairment of glucose tolerance * Tanner stages of puberty greater than B1, G1 * medical history of malignancy * therapy with growth hormone, glucocorticoides, anabolica * attending another clinical trial

What they're measuring

change of body proportion and final height

Timeframe: within 5 years

Trial details

NCT IDNCT00473187

SponsorUniversity of Rostock

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Hypophosphatemic Rickets trials